Spotlight on the Human Brain: Central Actions of SGLT2 Inhibitors?

Julia Hummel; Stephanie Kullmann; Martin Heni

doi:10.1210/clinem/dgac179

Spotlight on the Human Brain: Central Actions of SGLT2 Inhibitors?

J Clin Endocrinol Metab. 2022 Jun 16;107(7):e3080-e3081. doi: 10.1210/clinem/dgac179.

Authors

Julia Hummel^{1

2}, Stephanie Kullmann^{1

2

3}, Martin Heni^{1

2

3

4}

Affiliations

¹ Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, 72076 Tübingen, Germany.
² German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany.
³ Department of Internal Medicine, Division of Diabetology, Endocrinology and Nephrology, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.
⁴ Institute for Clinical Chemistry and Pathobiochemistry, Department for Diagnostic Laboratory Medicine, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.

No abstract available

Keywords: GLP-1 receptor agonist; SGLT2 inhibitor; body weight; central nervous system; dapagliflozin; exenatide; functional neuroimaging; obesity; satiety and reward circuits; type 2 diabetes.

Publication types

Editorial
Comment

MeSH terms

Benzhydryl Compounds
Brain
Cues
Diabetes Mellitus, Type 2* / drug therapy
Exenatide
Glucosides
Humans
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Benzhydryl Compounds
Glucosides
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
Exenatide